Welcome to our dedicated page for Alkermes Plc SEC filings (Ticker: ALKS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Alkermes plc (ALKS) SEC filings page on Stock Titan brings together the companys regulatory disclosures from the U.S. Securities and Exchange Commission, offering structured access to its Forms 8-K and other key documents. Alkermes is a global biopharmaceutical company focused on neuroscience, with commercial products for alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline that includes alixorexton, an investigational orexin 2 receptor agonist for narcolepsy and idiopathic hypersomnia.
Through its current reports on Form 8-K, Alkermes provides official details on material events. These include financial result announcements, where the company reports quarterly revenues, net income, EBITDA and adjusted EBITDA, along with updates to its annual financial expectations. Such filings often include reconciliations of non-GAAP measures like EBITDA and adjusted EBITDA and discuss revenue contributions from proprietary products and manufacturing and royalty arrangements.
Alkermes also uses Form 8-K to disclose clinical and regulatory milestones, such as positive topline results from phase 2 studies of alixorexton in narcolepsy type 1 and type 2, and to furnish related investor presentations. These documents help readers understand the design, endpoints and topline outcomes of the Vibrance studies and the companys plans for further development.
Another important category of filings relates to transaction agreements and financing. Alkermes has filed a transaction agreement and an amendment describing the terms under which it proposes to acquire Avadel Pharmaceuticals plc, including cash consideration per share and a non-transferable contingent value right linked to a potential regulatory milestone for LUMRYZ. The company has also filed an amended and restated bridge term loan credit agreement, outlining a senior secured bridge term loan facility intended to support financing of the proposed acquisition, along with associated covenants and security arrangements.
Stock Titan enhances these filings with AI-powered summaries that highlight the main points of lengthy documents, helping users quickly identify items such as earnings updates, clinical trial disclosures, transaction terms and new financing commitments. Real-time updates from EDGAR allow investors to see new ALKS filings as they appear, while structured access to exhibits makes it easier to review detailed agreements, credit facilities and presentation materials.
For those tracking insider and governance information, Alkermes broader SEC reporting framework also encompasses ownership and compensation disclosures in its periodic and proxy filings, which can be accessed alongside 8-Ks. Together, these documents form a detailed record of Alkermes financial condition, strategic transactions, development progress and capital structure.
Alkermes plc describes a global neuroscience-focused biopharmaceutical business built around proprietary drugs for alcohol and opioid dependence, schizophrenia, bipolar I disorder and narcolepsy, plus licensed and technology-partnered products.
The company completed the acquisition of Avadel Pharmaceuticals in February 2026, adding LUMRYZ, the first once-at-bedtime sodium oxybate for narcolepsy, and a dedicated commercial organization. Alkermes highlights key products ARISTADA, ARISTADA INITIO, LYBALVI and VIVITROL, royalty-generating collaborations with Janssen and Biogen, and a late-stage pipeline led by alixorexton, an orexin 2 receptor agonist with FDA Breakthrough Therapy designation in narcolepsy. The filing also outlines extensive patent protection, manufacturing arrangements, intense competitive pressures and numerous business risks, including reliance on a few major products, regulatory and IP challenges, debt obligations and potential volatility in its ordinary shares.
Alkermes plc reported 2025 total revenue of $1.48 billion, down from $1.56 billion, as royalties declined after the INVEGA SUSTENNA® U.S. royalty expiry, even though proprietary net sales rose to $1.18 billion. LYBALVI® grew to $346.7 million, ARISTADA® to $370.0 million and VIVITROL® to $467.9 million.
GAAP net income for 2025 was $241.7 million, or $1.43 diluted EPS, compared with $367.1 million and $2.17 in 2024, and Adjusted EBITDA declined to $394.0 million. The company closed its Avadel acquisition, using about $775 million of cash and adding $1.525 billion of term loans, gaining LUMRYZ® and a stronger sleep-medicine franchise. For 2026, Alkermes expects revenues of $1.73–$1.84 billion, proprietary net sales driven by VIVITROL®, LYBALVI®, ARISTADA® and LUMRYZ®, but a GAAP net loss of $(115)–$(135) million and Adjusted EBITDA of $370–$410 million as it absorbs Avadel-related costs and ramps its orexin portfolio.
Alkermes plc VP, Finance (Interim PAO) Samuel Joseph Parisi reported equity award transactions involving restricted stock units (RSUs) and ordinary shares. On February 18 and 19, 2026, RSU awards were exercised, converting 2,034 and 2,991 RSUs into the same number of ordinary shares at a price of $0.00 per share.
To cover tax obligations, Parisi disposed of 706 ordinary shares at $32.02 and 979 ordinary shares at $32.00 through share withholding transactions coded "F," which are described as payments of tax liability by delivering securities. After these transactions, he directly held 11,057 ordinary shares. Footnotes state that each RSU represents a right to one ordinary share, that one award is fully vested, and another vests in four equal annual installments starting on February 19, 2026.
Alkermes plc SVP and Chief Commercial Officer Christian Todd Nichols reported equity award activity involving restricted stock units (RSUs) and ordinary shares. On February 18 and 19, 2026, RSU awards covering 6,355 and 6,045 units were exercised, with each unit converting into one ordinary share at a price of $0.00 per share.
Following these conversions, Nichols’ direct holdings in ordinary shares increased, with post-transaction balances of 107,301 and 111,477 shares reported. On both dates, the company also withheld 1,869 and 2,277 ordinary shares, respectively, at around $32 per share to cover tax obligations, reducing the final reported balance to 109,200 and then 105,432 shares. Footnotes state that one award is fully vested and another vests in four equal annual installments starting on February 19, 2026.
Alkermes plc executive Jackson Blair Curtis, EVP and Chief Operating Officer, exercised restricted stock units into ordinary shares and delivered shares to cover taxes. On February 18–19, 2026, he converted a total of 18,197 RSUs into ordinary shares.
To satisfy tax withholding, 7,926 ordinary shares were disposed of at prices around $32 per share, described as payment of tax liability rather than open‑market sales. After these transactions, he held 231,823 ordinary shares directly. One RSU award is fully vested, and another vests in four equal annual installments starting February 19, 2026.
Alkermes plc EVP R&D and Chief Medical Officer Craig C. Hopkinson reported equity compensation-related share movements, primarily from restricted stock units (RSUs) converting into ordinary shares. On February 18 and 19, 2026, RSU awards for 8,897 and 7,673 units were exercised, each unit representing one ordinary share.
To cover tax obligations associated with these vestings, 3,504 and 3,407 ordinary shares were automatically withheld and disposed of at prices of $32.02 and $32.00 per share, respectively, characterized as payment of tax liability rather than open-market sales. Following these transactions, Hopkinson directly owned 81,031 Alkermes ordinary shares. One referenced RSU award is noted as fully vested, while another vests in four equal annual installments starting on February 19, 2026.
Alkermes plc executive David Joseph Gaffin reported multiple equity award transactions. On February 18 and 19, 2026, he exercised restricted stock unit awards into ordinary shares, with each unit converting into one ordinary share.
He acquired 7,673 ordinary shares and 6,355 ordinary shares through derivative exercises at a stated price of $0.00 per share. On the same dates, he disposed of 3,407 and 2,126 ordinary shares, respectively, to cover tax liabilities through share withholding. After these transactions, his directly held ordinary shares totaled 231,602. One award is fully vested, while another vests in four equal annual installments starting on February 19, 2026.
Baker Bros. Advisors LP and related entities filed a Schedule 13G reporting beneficial ownership of 10,012,267 Alkermes plc ordinary shares, equal to 6.1% of the class, based on 165,117,509 shares outstanding as of October 24, 2025.
The shares are held through two investment funds: 667, L.P. with 845,828 shares (0.5%) and Baker Brothers Life Sciences, L.P. with 9,166,439 shares (5.6%). The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Alkermes.
Alkermes plc completed its acquisition of Avadel Pharmaceuticals plc, gaining the FDA‑approved narcolepsy drug LUMRYZ and a commercial team experienced in sleep medicine. The deal was executed via an Irish court‑sanctioned scheme of arrangement.
Avadel shareholders became entitled to receive $21.00 in cash per share plus one contingent value right that may pay an additional $1.50 per share if a specified milestone in the CVR agreement is met. Avadel will be delisted from Nasdaq and deregistered under U.S. securities laws.
To finance the Acquisition, Alkermes borrowed $1.525 billion under new senior secured term loan A and B facilities maturing in 2031 and used approximately $750 million of its cash. A prior bridge term loan facility of about $1.5 billion was terminated. Alkermes states the transaction is expected to be accretive in 2026 and to enhance its revenue growth profile while expanding its neuroscience portfolio and late‑stage pipeline in sleep and other neurological disorders.
Alkermes plc Director and CEO Richard F. Pops reported two transactions in ordinary shares. On February 5, 2026, he acquired 149,580 ordinary shares at no cost from the vesting of performance-based restricted stock units granted in February 2023 after a three-year performance period.
On the same date, he disposed of 62,230 ordinary shares at $33.55 per share. Following these transactions, Pops beneficially owned 1,377,740 ordinary shares directly.